Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALBT Avalon GloboCare	$2.19 -2.7%	$2.64	$1.87 ▼ $11.66	$4.26M	-0.02	1.45 million shs	35,931 shs
ATXI Avenue Therapeutics	$0.52 +4.0%	$0.35	$0.17 ▼ $3.54	$1.66M	N/A	181,127 shs	53,134 shs
INM InMed Pharmaceuticals	$2.34 +4.0%	$2.70	$1.72 ▼ $15.70	$4.50M	0.29	68,942 shs	96,814 shs
TCRT Alaunos Therapeutics	$2.40 +0.4%	$3.63	$1.31 ▼ $6.20	$3.92M	-0.81	49,698 shs	23,712 shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALBT Avalon GloboCare	-2.67%	-7.20%	-15.77%	-41.13%	-69.47%
ATXI Avenue Therapeutics	-9.34%	+57.58%	+48.40%	+136.26%	-78.78%
INM InMed Pharmaceuticals	+4.00%	+4.46%	-15.83%	-20.68%	-21.11%
TCRT Alaunos Therapeutics	+0.42%	-7.69%	-28.99%	-15.49%	-0.83%

Compare MarketRank™

Company	Overall Score	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALBT Avalon GloboCare	1.1807 of 5 stars	2.0	4.3	2.4	1.7	0.0
ATXI Avenue Therapeutics	1.649 of 5 stars	3.0	4.6	0.6	0.0	1.9
INM InMed Pharmaceuticals	1.3388 of 5 stars	5.0	0.0	3.4	0.0	0.6
TCRT Alaunos Therapeutics	1.2371 of 5 stars	5.0	0.0	3.5	0.8	0.0

Compare Analyst Forecasts

Company	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALBT Avalon GloboCare	N/A	N/A	N/A
ATXI Avenue Therapeutics	N/A	N/A	N/A
INM InMed Pharmaceuticals	N/A	N/A	N/A
TCRT Alaunos Therapeutics	N/A	N/A	N/A

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALBT Avalon GloboCare	$1.33M	3.11	N/A	N/A	($11.37) per share	-0.19
ATXI Avenue Therapeutics	N/A	N/A	N/A	N/A	$1.92 per share	N/A
INM InMed Pharmaceuticals	$4.60M	1.02	N/A	N/A	$20.64 per share	0.11
TCRT Alaunos Therapeutics	$10K	393.60	N/A	N/A	$1.29 per share	1.86

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALBT Avalon GloboCare	-$7.90M	-$19.96	N/A	∞	N/A	-647.29%	N/A	-50.13%	8/18/2025 (Estimated)
ATXI Avenue Therapeutics	-$10.38M	-$7.49	0.03	∞	N/A	N/A	-471.57%	-296.50%	N/A
INM InMed Pharmaceuticals	-$7.68M	-$12.09	N/A	∞	N/A	-168.87%	-107.93%	-82.97%	9/26/2025 (Estimated)
TCRT Alaunos Therapeutics	-$4.68M	-$2.54	N/A	∞	N/A	N/A	-169.34%	-124.28%	N/A

Latest ATXI, TCRT, INM, and ALBT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	ALBT Avalon GloboCare	N/A	-$2.02	N/A	-$6.22	N/A	N/A
8/14/2025	Q2 2025	TCRT Alaunos Therapeutics	N/A	-$0.63	N/A	-$0.63	N/A	N/A
5/15/2025	Q1 2025	TCRT Alaunos Therapeutics	-$4.50	-$0.67	+$3.83	-$0.67	N/A	$0.00 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALBT Avalon GloboCare	N/A	N/A	N/A	N/A	N/A
ATXI Avenue Therapeutics	N/A	N/A	N/A	N/A	N/A
INM InMed Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
TCRT Alaunos Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALBT Avalon GloboCare	N/A	0.19	0.19
ATXI Avenue Therapeutics	N/A	2.70	2.70
INM InMed Pharmaceuticals	0.06	3.49	3.04
TCRT Alaunos Therapeutics	N/A	1.00	1.00

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALBT Avalon GloboCare	1.42%
ATXI Avenue Therapeutics	17.34%
INM InMed Pharmaceuticals	20.12%
TCRT Alaunos Therapeutics	27.72%

Insider Ownership

Company	Insider Ownership
ALBT Avalon GloboCare	37.30%
ATXI Avenue Therapeutics	1.80%
INM InMed Pharmaceuticals	1.43%
TCRT Alaunos Therapeutics	16.14%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALBT Avalon GloboCare	5	1.89 million	1.19 million	Not Optionable
ATXI Avenue Therapeutics	4	3.18 million	2.02 million	Not Optionable
INM InMed Pharmaceuticals	10	2.00 million	1.97 million	Not Optionable
TCRT Alaunos Therapeutics	40	1.64 million	1.38 million	No Data

ATXI, TCRT, INM, and ALBT Headlines

Recent News About These Companies

Alaunos Therapeutics’ Innovative Glioblastoma Study Completes: Market Implications

August 12 at 8:39 PM | msn.com

Alaunos Therapeutics Appoints Holger Weis as New CEO

July 25, 2025 | theglobeandmail.com

Alaunos Therapeutics Taps Board Member Weis as Next CEO

July 2, 2025 | marketwatch.com

Alaunos Therapeutics, Inc. (TCRT) - Yahoo Finance

June 26, 2025 | finance.yahoo.com

Alaunos Therapeutics Raises $850,000 in Private Offering

June 26, 2025 | tipranks.com

Alaunos Therapeutics Announces $2.0 Million Registered Direct Offering - Morningstar

June 24, 2025 | morningstar.comM

Alaunos Therapeutics Announces $2.0 Million Registered Direct Offering

June 23, 2025 | globenewswire.com

Alaunos Therapeutics Amends Warrant Agreement with Mast Hill

June 10, 2025 | tipranks.com

PMGC Capital LLC, a Subsidiary of PMGC Holdings Inc. (Nasdaq: ELAB), To File Schedule 13D Reporting 5.09% Stake in Alaunos Therapeutics, Inc. (Nasdaq: TCRT)

May 14, 2025 | globenewswire.com

Alaunos Therapeutics announces board member resignation

April 20, 2025 | investing.com

These 3 Healthcare Stocks Show Serious Muscle Amid Trump Tariff Turmoil: Are Retail Traders Feeling Bullish?

April 7, 2025 | msn.com

Precigen Terminates License Agreement With Alaunos Therapeutics

October 11, 2024 | marketwatch.com

After axing its sole clinical prospect last year, Alaunos cuts ties with Precigen

October 11, 2024 | fiercebiotech.comF

Alaunos Therapeutics Ends Licensing Deal, Reassesses Strategy

October 11, 2024 | finance.yahoo.com

Alaunos Therapeutics (NASDAQ:TCRT) Stock, Short Interest Report

September 26, 2024 | benzinga.com

Alaunos Therapeutics (NASDAQ:TCRT) Stock Quotes, Forecast and News Summary

September 26, 2024 | benzinga.com

Stella Pharma Corporation (4888.T) Stock Price, News, Quote & History - Yahoo Finance

September 24, 2024 | finance.yahoo.com

TCRT Stock Earnings: Alaunos Therapeutics Reported Results for Q1 2024

May 15, 2024 | investorplace.com

Revolution Medicines: An Expensive Shot At A Massive Market Opportunity

April 12, 2024 | seekingalpha.com

TCRT Stock Earnings: Alaunos Therapeutics Misses EPS for Q4 2023

April 8, 2024 | investorplace.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

ATXI, TCRT, INM, and ALBT Company Descriptions

Avalon GloboCare NASDAQ:ALBT

$2.19 -0.06 (-2.67%)

Closing price 08/14/2025 04:00 PM Eastern

Extended Trading

$2.24 +0.05 (+2.28%)

As of 08/14/2025 07:37 PM Eastern

Avalon GloboCare Corp., together with its subsidiaries, owns and operates commercial real estate properties in the United States and China. The company develops and delivers transformative cellular therapeutics, precision diagnostics, and clinical laboratory services. Its leading candidates are AVA-001, an anti-CD19 CAR-T, which has completed first-in-human clinical trial for relapsed/refractory (R/R) B-cell lymphoblastic leukemia; and AVA-011 that has completed pre-clinical laboratory studies and undergoing IND-enabling process development stage to generate cGMP-grade AVA-011 CAR-T cells. It is also developing mRNA-based Flash-CAR cell therapy platform. In addition, the company develops Avalon clinical-grade tissue-specific exosome (ACTEX); AVA-Trap, a therapeutic program provides an effective therapeutic option to combat COVID-19 and other life-threatening conditions involving cytokine storms; offers therapeutic and diagnostic targets utilizing QTY-code protein design technology with Massachusetts Institute of Technology (MIT), including using the QTY code protein design technology for development of a hemofiltration device to treat Cytokine Storm; and provides co-development of next generation, transposon-based, multi-target CAR-T, CAR-NK, and other immune effector cell therapeutic modalities with Arbele Limited. Avalon GloboCare Corp. has strategic partnership with HydroPeptide, LLC to engage in co-development and commercialization of a series of clinical-grade, exosome-based cosmeceutical, and orthopedic products; and corporate research agreement with the University of Pittsburgh of the Commonwealth System of Higher Education. The company was founded in 2016 and is headquartered in Freehold, New Jersey.

Avenue Therapeutics NASDAQ:ATXI

$0.52 +0.02 (+4.00%)

As of 08/14/2025 03:10 PM Eastern

Avenue Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. Its product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders. The company was incorporated in 2015 and is based in Bay Harbor Islands, Florida.

InMed Pharmaceuticals NASDAQ:INM

$2.34 +0.09 (+4.00%)

Closing price 08/14/2025 04:00 PM Eastern

Extended Trading

$2.29 -0.05 (-2.14%)

As of 08/14/2025 07:39 PM Eastern

InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products. The company operates through two segments, the InMed and the BayMedica. The InMed segment researches and develops cannabinoid-based pharmaceuticals products. The BayMedica segment develops proprietary manufacturing technologies to produce and sell rare cannabinoids for the health and wellness industry. Its prescription-based products include rare cannabinoids and novel cannabinoid analogs for the treatment of diseases with high unmet medical needs. The company's lead product is INM-755, a cannabinol topical skin cream, completed Phase 2 clinical trial for the treatment of epidermolysis bullosa. It also develops INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-900 for neurodegenerative diseases. In addition, the company offers IntegraSyn, an integrated biosynthesis-based manufacturing approach, for pharmaceutical-grade cannabinoids; and cannabichromene, cannabicitran, cannabidivarin, and tetrahydrocannabivarin. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.

Alaunos Therapeutics NASDAQ:TCRT

$2.40 +0.01 (+0.42%)

Closing price 08/14/2025 04:00 PM Eastern

Extended Trading

$2.42 +0.02 (+0.63%)

As of 08/14/2025 04:06 PM Eastern

Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive T-cell receptor (TCR) engineered T-cell therapies (TCR-T) to treat multiple solid tumor types. It develops Library TCR-T Cell Theraphy, which is in Phase I/II clinical trial for 12 TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers. The company is also developing hunTR, a human neoantigen TCR discovery engine; and Sleeping Beauty Gene Transfer Platform, a non-viral genetic engineering technology. The company was founded in 2003 and is headquartered in Houston, Texas.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time